Dexamethasone Intravitreal Implant (OZURDEX^®) for Macular Edema Secondary to Noninfectious Uveitis: a Review of the Literature

References

• Jabs DA . Epidemiology of uveitis. Ophthalmic Epidemiol.15(5), 283–284 (2008).
   PubMed Web of Science ®Google Scholar
• Gritz DC , WongIG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology111(3), 491–500 (2004).
   PubMed Web of Science ®Google Scholar
• Rehman I , MahabadiN , PatelBC. Anatomy, head and neck, eye. In: StatPearls. StatPearls PublishingFL, USA (2019).
   Google Scholar
• Deschenes J , MurrayPI , RaoNA , NussenblattRB. International Uveitis Study G. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul. Immunol. Inflamm.16(1), 1–2 (2008).
   PubMed Web of Science ®Google Scholar
• Lardenoye CW , van KooijB , RothovaA. Impact of macular edema on visual acuity in uveitis. Ophthalmology113(8), 1446–1449 (2006).
   PubMed Web of Science ®Google Scholar
• Fardeau C , ChampionE , MassambaN , LeHoangP. Uveitic macular edema. Eye (Lond.)30(10), 1277–1292 (2016).
   PubMed Web of Science ®Google Scholar
• Rothova A , Suttorp-vanSchulten MS , FritsTreffers W , KijlstraA. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br. J. Ophthalmol.80(4), 332–336 (1996).
   PubMed Web of Science ®Google Scholar
• Cordero Coma M , SobrinL , OnalS , ChristenW , FosterCS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology114(8), 1574–1579, e1571 (2007).
   PubMed Web of Science ®Google Scholar
• Bajwa A , OsmanzadaD , OsmanzadaSet al. Epidemiology of uveitis in the mid-Atlantic United States. Clin. Ophthalmol.9, 889–901 (2015).
   PubMed Web of Science ®Google Scholar
• Rothova A . Medical treatment of cystoid macular edema. Ocul. Immunol. Inflamm.10(4), 239–246 (2002).
   PubMed Web of Science ®Google Scholar
• Waterbury LD , SillimanD , JolasT. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr. Med. Res. Opin.22(6), 1133–1140 (2006).
   PubMed Web of Science ®Google Scholar
• Goldhardt R , RosenBS. Uveitic macular edema: treatment update. Curr. Ophthalmol. Rep.4(1), 30–37 (2016).
   PubMedGoogle Scholar
• van Haeringen NJ , van SorgeAA , CarballosaCore-Bodelier VM. Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S(+) flurbiprofen. J. Ocul. Pharmacol. Ther.16(4), 353–361 (2000).
   PubMed Web of Science ®Google Scholar
• Jones J , FrancisP. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin. Pharmacother.10(14), 2379–2385 (2009).
   PubMed Web of Science ®Google Scholar
• Hariprasad SM , AkdumanL , CleverJA , OberM , RecchiaFM , MielerWF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin. Ophthalmol.3, 147–154 (2009).
   PubMedGoogle Scholar
• Wielders LHP , SchoutenJ , WinkensBet al. European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1. J. Cataract Refract. Surg.44(4), 429–439 (2018).
   PubMed Web of Science ®Google Scholar
• Radwan AE , ArcinueCA , YangP , ArtornsombudhP , AbuAl-Fadl EM , FosterCS. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes. Arch. Clin. Exp. Ophthalmol.251(7), 1801–1806 (2013).
   PubMed Web of Science ®Google Scholar
• Angunawela RI , HeatleyCJ , WilliamsonTHet al. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular edema: longterm management and outcome. Acta Ophthalmol. Scand.83(5), 595–599 (2005).
   PubMedGoogle Scholar
• Weijtens O , FeronEJ , SchoemakerRCet al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am. J. Ophthalmol.128(2), 192–197 (1999).
   PubMed Web of Science ®Google Scholar
• Venkatesh P , KumarCS , AbbasZ , GargS. Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocul. Immunol. Inflamm.16(5), 217–223 (2008).
   PubMed Web of Science ®Google Scholar
• Leder HA , JabsDA , GalorA , DunnJP , ThorneJE. Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am. J. Ophthalmol.152(3), 441–448, e442 (2011).
   PubMed Web of Science ®Google Scholar
• Jea SY , ByonIS , OumBS. Triamcinolone-induced intraocular pressure elevation: intravitreal injection for macular edema and posterior subtenon injection for uveitis. Korean J. Ophthalmol.20(2), 99–103 (2006).
   PubMedGoogle Scholar
• Byun YS , ParkYH. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J. Ocul. Pharmacol. Ther.25(2), 159–162 (2009).
   PubMed Web of Science ®Google Scholar
• Panos GD . Evolution of intravitreal therapy for retinal and macular disorders. J. Int. Med. Res. doi:10.1177/0300060518771411 (2018) (Epub ahead of print).
   Google Scholar
• Cunningham MA , EdelmanJL , KaushalS. Intravitreal steroids for macular edema: the past, the present, and the future. Surv. Ophthalmol.53(2), 139–149 (2008).
   PubMed Web of Science ®Google Scholar
• Roth DB , VermaV , RealiniT , PrennerJL , FeuerWJ , FechtnerRD. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology116(3), 455–460 (2009).
   PubMed Web of Science ®Google Scholar
• Galor A , MargolisR , BrasilOMet al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology114(10), 1912–1918 (2007).
   PubMed Web of Science ®Google Scholar
• Venkatesh P , AbhasZ , GargS , VohraR. Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis. Graefes. Arch. Clin. Exp. Ophthalmol.245(1), 59–67 (2007).
   PubMed Web of Science ®Google Scholar
• Androudi S , TsironiE , KalogeropoulosC , TheodoridouA , BrazitikosP. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology117(8), 1612–1616 (2010).
   PubMed Web of Science ®Google Scholar
• Tranos PG , WickremasingheSS , StangosNT , TopouzisF , TsinopoulosI , PavesioCE. Macular edema. Surv. Ophthalmol.49(5), 470–490 (2004).
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN , TheodossiadisPG , PanteliaE , PapaefthimiouS , TheodossiadisGP , SfikakisPP. Infliximab for chronic cystoid macular edema associated with uveitis. Am. J. Ophthalmol.138(4), 648–650 (2004).
   PubMed Web of Science ®Google Scholar
• Haller JA , BandelloF , BelfortR , Jret al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology118(12), 2453–2460 (2011).
   PubMed Web of Science ®Google Scholar
• Lowder C , BelfortR , Jr , LightmanSet al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch. Ophthalmol.129(5), 545–553 (2011).
   PubMed Web of Science ®Google Scholar
• Williams GA , HallerJA , KuppermannBDet al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am. J. Ophthalmol.147(6), 1048–1054, 1054 e1041–1042 (2009).
   PubMed Web of Science ®Google Scholar
• Scaramuzzi M , QuerquesG , SpinaCL , LattanzioR , BandelloF. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina35(6), 1216–1222 (2015).
   PubMed Web of Science ®Google Scholar
• Garweg JG , ZandiS. Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex(R)) in its treatment. Graefes. Arch. Clin. Exp. Ophthalmol.254(7), 1257–1265 (2016).
   PubMed Web of Science ®Google Scholar
• Khan Z , KuriakoseRK , KhanM , ChinEK , AlmeidaDR. Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: meta-analysis and clinical implications. Ophthalmic Surg. Lasers Imaging Retina48(2), 160–166 (2017).
   PubMed Web of Science ®Google Scholar
• Multicenter Uveitis Steroid Treatment Trial Research G , KempenJH , AltaweelMMet al.Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology118(10), 1916–1926 (2011).
   PubMed Web of Science ®Google Scholar
• Kwak HW , D’AmicoDJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch. Ophthalmol.110(2), 259–266 (1992).
   PubMed Web of Science ®Google Scholar
• London NJ , ChiangA , HallerJA. The dexamethasone drug delivery system: indications and evidence. Adv. Ther.28(5), 351–366 (2011).
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE , AttarM , AcheampongAAet al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest. Ophthalmol. Vis. Sci.52(1), 80–86 (2011).
   PubMed Web of Science ®Google Scholar
• Arcinue CA , CeronOM , FosterCS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J. Ocul. Pharmacol. Ther.29(5), 501–507 (2013).
   PubMed Web of Science ®Google Scholar
• Breitbach M , RackD , DietzelM , HeinzC , HeiligenhausA. [Efficacy of a dexamethasone implant for the treatment of refractory cystoid macular edema in non-infectious uveitis]. Klin. Monbl. Augenheilkd233(5), 601–605 (2016).
   PubMed Web of Science ®Google Scholar
• Nobre-Cardoso J , ChampionE , DarugarA , FelA , LehoangP , BodaghiB. Treatment of non-infectious uveitic macular edema with the intravitreal dexamethasone implant. Ocul. Immunol. Inflamm.25(4), 447–454 (2017).
   PubMed Web of Science ®Google Scholar
• Ratra D , BarhA , BanerjeeM , RatraV , BiswasJ. Safety and efficacy of intravitreal dexamethasone implant for refractory uveitic macular edema in adults and children. Ocul. Immunol. Inflamm.26(7), 1034–1040 (2018).
   PubMed Web of Science ®Google Scholar
• Fabiani C , VitaleA , EmmiGet al. Systemic steroid sparing effect of intravitreal dexamethasone implant in chronic noninfectious uveitic macular edema. J. Ocul. Pharmacol. Ther.33(7), 549–555 (2017).
   PubMed Web of Science ®Google Scholar
• Zola M , BriamonteC , LorenziU , MachettaF , GrignoloFM , FeaAM. Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone. Clin. Ophthalmol.11, 1949–1956 (2017).
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O , TaylorSR , BarAet al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology121(8), 1649–1654 (2014).
   PubMed Web of Science ®Google Scholar
• Tsang AC , VirgiliG , AbtahiM , GottliebCC. Intravitreal dexamethasone implant for the treatment of macular edema in chronic non-infectious uveitis. Ocul. Immunol. Inflamm.25(5), 685–692 (2017).
   PubMed Web of Science ®Google Scholar
• Bansal P , AgarwalA , GuptaV , SinghR , GuptaA. Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex(R) in patients with uveitic cystoid macular edema. Indian J. Ophthalmol.63(5), 416–422 (2015).
   PubMed Web of Science ®Google Scholar
• Khurana RN , PorcoTC. Efficacy and safety of dexamethasone intravitreal implant for persistent uveitic cystoid macular edema. Retina35(8), 1640–1646 (2015).
   PubMed Web of Science ®Google Scholar
• Bernard Y , BonninN , FarguetteF , ChiambarettaF. [Tolerability and short-term efficacy of the Ozurdex(R) dexamethasone intravitreal implant for treatment of uveitic cystoid macular edema: a retrospective study of 52 injections performed at the Clermont-Ferrand teaching hospital]. J. Fr. Ophtalmol.39(1), 1–4 (2016).
   PubMed Web of Science ®Google Scholar
• Sorkin N , LoewensteinA , Habot-WilnerZ , GoldsteinM. Intravitreal dexamethasone implant in patients with persistent macular edema of variable etiologies. Ophthalmologica232(2), 83–91 (2014).
   PubMed Web of Science ®Google Scholar
• Cao JH , MulvahillM , ZhangL , JoondephBC , DaceyMS. Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology121(10), 1871–1876 (2014).
   PubMed Web of Science ®Google Scholar
• Khurana RN , BansalAS , ChangLK , PalmerJD , WuC , WielandMR. Prospective evaluation of a sustained-release dexamethasone intravitreal implant for cystoid macular edema in quiescent uveitis. Retina37(9), 1692–1699 (2017).
   PubMed Web of Science ®Google Scholar
• Carbonniere C , CouretC , BleriotAet al. [Treatment of macular edema: comparison of efficacy and tolerability of subconjunctival triamcinolone injections, sub-tenon’s triamcinolone injections and intravitreal dexamethasone implant]. J. Fr. Ophtalmol.40(3), 177–186 (2017).
   PubMed Web of Science ®Google Scholar
• Winterhalter S , BehrensUD , SalchowD , JoussenAM , PleyerU. Dexamethasone implants in paediatric patients with noninfectious intermediate or posterior uveitis: first prospective exploratory case series. BMC Ophthalmol.17(1), 252 (2017).
   PubMedGoogle Scholar
• Agarwal A , HandaS , AggarwalKet al. The role of dexamethasone implant in the management of tubercular uveitis. Ocul. Immunol. Inflamm.26(6), 884–892 (2017).
   PubMed Web of Science ®Google Scholar
• Lautredou CC , HardinJS , ChancellorJR , UwaydatSH , EllabbanAA , SallamAB. Repeat intravitreal dexamethasone implant for refractory cystoid macular edema in syphilitic uveitis. Case Rep. Ophthalmol. Med. 2018, 7419823 (2018).
   PubMedGoogle Scholar
• Adan A , PelegrinL , ReyAet al. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina33(7), 1435–1440 (2013).
   PubMed Web of Science ®Google Scholar
• Garweg JG , BaglivoE , FreibergFJet al. Response of postoperative and chronic uveitic cystoid macular edema to a dexamethasone-based intravitreal implant (Ozurdex). J. Ocul. Pharmacol. Ther.32(7), 442–450 (2016).
   PubMed Web of Science ®Google Scholar
• Pelegrin L , dela Maza MS , MolinsB , RiosJ , AdanA. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis. Eye (Lond.)29(7), 943–950 (2015).
   PubMed Web of Science ®Google Scholar
• Frere A , CaspersL , MakhoulDet al. Single dexamethasone intravitreal implant in the treatment of noninfectious uveitis. J. Ocul. Pharmacol. Ther.33(4), 290–297 (2017).
   PubMed Web of Science ®Google Scholar
• Kucukevcilioglu M , ErenM , YolcuU , SobaciG. Acute retinal necrosis following intravitreal dexamethasone (Ozurdex(R)) implant. Arq. Bras. Oftalmol.78(2), 118–119 (2015).
   PubMed Web of Science ®Google Scholar
• Olson DJ , ParhizAT , WirthlinRS. Reactivation of latent toxoplasmosis following dexamethasone implant injection. Ophthalmic Surg. Lasers Imaging Retina47(11), 1050–1052 (2016).
   PubMed Web of Science ®Google Scholar
• Bourgault S , AroichaneM , WittenbergLA , LavalleeA , MaPE. Treatment of refractory uveitic macular edema with dexamethasone intravitreal implants in a pediatric patient with bilateral granulomatous idiopathic panuveitis: a case report. J. Ophthalmic Inflamm. Infect.3(1), 61 (2013).
   PubMedGoogle Scholar
• Squires H , PokuE , BermejoIet al. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technol. Assess21(68), 1–170 (2017).
   PubMed Web of Science ®Google Scholar
• Squires H , BermejoI , PokuENet al. Dexamethasone implant for non-infectious uveitis: is it cost-effective? Br. J. Ophthalmol. (2019). doi: 10.1136/bjophthalmol-2018-312765 ( Epub ahead of print).
   Web of Science ®Google Scholar